From Value Line's post-earnings Supplemental Report
Value line seldom has better than a Neutral rating on Pfizer largely because it insists on using GAAP accounting (notice the $1.25 forecast that it is using).
Pfizer is the ONLY big, domestic pharma where Value Line uses GAAP - for MRK which last year only reported a few dimes per share in GAAP earnings, Value Line shows the non-GAAP figure of $3.77. Moreover, Value Line shows GAAP results and estimates for Pfizer only for the years 2008 and thereafter; all stats through 2007 are non-GAAP.
On occasions I've been sorely tempted to cancel my subscription with them but I just can't afford to not be without their 15-year history of revenues, stock price ranges and in most cases non-GAAP earnings.
However, the commentary and PE multiples are most unfair when Value Line uses GAAP for Pfizer and non-GAAP for everyone else.
ALL of MY posts are posts in actual fact. I don't just deal in facts, I deal in actual facts. I may not be able to prove the things that I post, and others may refute MY posts with so called authoritative sources, but I know what I heard in the course of MY travels and whatever it was, must still be true today if I remember correctly. How do you like them apples Johnboy?
I am very unpopular here and this isn't exactly the first useful message I have posted that the multi-aliased riff-raff has rated one star. Persaonlly, I don't give a hoot - I continue to post meaningful messages of interest and however they are rated, they are rated.